Bridging the translational gap in HNSCC immunotherapy: From resistance mechanisms to high-fidelity preclinical models
Shasha Shen1, Juan Li1, Xue Cui1
1Department of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) remains a therapeutic challenge, with immune checkpoint inhibitors (ICIs) benefiting only a minority of patients. This review addresses the translational gap between promising preclinical results and suboptimal clinical outcomes. We critically analyze biological resistance drivers, including the immunosuppressive tumor microenvironment, TGF-β-mediated exclusion, hypoxia-driven metabolic checkpoints (e.g., adenosine signaling), and the distinct immune landscapes of HPV-positive versus HPV-negative disease. We argue that conventional models, such as 2D cell lines, syngeneic mice, and standard immunodeficient xenografts, inadequately recapitulate these human-specific mechanisms and stromal complexities. Consequently, we advocate for a paradigm shift toward high-fidelity platforms, specifically Air-Liquid Interface (ALI) autologous patient-derived organoids (PDOs) and humanized mouse models. While acknowledging technical challenges like establishment efficiency and time-to-answer constraints, we propose that integrating these avatars into biomarker-driven co-clinical trials is essential. Ultimately, integrating these high-fidelity avatars into co-clinical trials will enable precise patient stratification and the rational design of biomarker-driven trials, moving HNSCC therapy from empirical selection to data-driven clinical decision-making. Furthermore, standardizing these high-fidelity protocols to meet clinical turnaround times is the next frontier for ensuring their practical implementation in routine precision oncology for HNSCC.
Insights
Head and neck squamous cell carcinoma (HNSCC) shows limited response to immune checkpoint inhibitors (ICIs). High-fidelity models like patient-derived organoids are crucial for developing effective, biomarker-driven HNSCC therapies.
Area of Science:
- Oncology
- Immunotherapy
- Translational Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) presents a significant therapeutic challenge, with immune checkpoint inhibitors (ICIs) offering benefit to only a subset of patients.
- A critical translational gap exists between preclinical findings and clinical outcomes in HNSCC immunotherapy.
Purpose of the Study:
- To analyze biological resistance mechanisms in HNSCC.
- To evaluate the limitations of conventional preclinical models.
- To advocate for advanced, high-fidelity models for improved HNSCC treatment strategies.
Main Methods:
- Critical analysis of resistance drivers: immunosuppressive tumor microenvironment, TGF-β, hypoxia-driven metabolic checkpoints (adenosine signaling), and HPV status.
- Evaluation of conventional models (2D cell lines, syngeneic mice, immunodeficient xenografts).
- Proposal of high-fidelity platforms: Air-Liquid Interface (ALI) autologous patient-derived organoids (PDOs) and humanized mouse models.
Main Results:
- Conventional models inadequately recapitulate human-specific resistance mechanisms and stromal complexities in HNSCC.
- High-fidelity models like ALI PDOs and humanized mice offer superior recapitulation of HNSCC biology.
- Integration into biomarker-driven co-clinical trials is proposed as essential for advancing HNSCC therapy.
Conclusions:
- A paradigm shift towards high-fidelity preclinical models is necessary for HNSCC immunotherapy.
- These advanced models facilitate precise patient stratification and rational trial design.
- Standardization of high-fidelity protocols is key for clinical implementation in precision oncology for HNSCC.
More Related Videos
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
07:08A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Related Concept Videos
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Tumor Immunotherapy
Gap Junctions
Gap Junctions
Wheatstone Bridge
Thus, for accurate resistance measurements, a...
